Form 4: enGene Holdings Director Michael Heffernan Granted 45,000 Stock Options

enGene Holdings Inc. Director Michael Thomas Heffernan was granted 45,000 stock options with an exercise price of $3.83, vesting over three years following his appointment to the Board.

Summary

• Michael Thomas Heffernan, a Director of enGene Holdings Inc. (ENGN), was granted 45,000 stock options.
• The options have an exercise price of $3.83 per share.
• The transaction date for this grant was July 8, 2025.
• The options will vest in three equal annual installments, with 1/3 vesting on the first, second, and third anniversaries of Mr. Heffernan's appointment to the Board, which occurred on July 8, 2025.
• The expiration date for these stock options is July 8, 2035.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the grant of options aligns director interests with shareholders and is a standard, expected corporate action, indicating stable governance and compensation practices.

Positives

• The grant of stock options aligns the financial interests of Director Michael Thomas Heffernan with those of enGene Holdings Inc. shareholders, incentivizing long-term performance.
• This is a standard compensation practice for board members, indicating a structured approach to executive and director remuneration.

Future Outlook

The stock options granted to Director Michael Thomas Heffernan are subject to a vesting schedule, with 1/3 of the options vesting on each of the first, second, and third anniversaries of his July 8, 2025, appointment date, indicating a future commitment and performance incentive structure.

Industry Context

The granting of stock options to directors is a common practice across various industries, particularly in biotechnology and growth-oriented companies, to attract and retain talent, and to align leadership interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice in the biotechnology and pharmaceutical sectors, comparable to compensation structures seen in companies like Moderna, BioNTech, or Regeneron, which often use equity incentives to align leadership with long-term R&D and commercialization goals.
• The vesting schedule of one-third per year over three years is a common industry standard for equity grants to ensure continued commitment and performance over a multi-year period, similar to practices at companies such as Gilead Sciences or Amgen for their board members.

Management Changes

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Michael Thomas Heffernan constitutes an insider transaction, as he is a related party to enGene Holdings Inc. by virtue of his board position.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially leading to better long-term performance, but also introduces a minor potential for future share dilution upon exercise.
• Employees: While not directly impacting general employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The stock options will vest in three annual installments, with the first vesting occurring on July 8, 2026, the second on July 8, 2027, and the third on July 8, 2028.
• Director Heffernan may choose to exercise his vested options at any point before the expiration date of July 8, 2035.

Key Dates

Keywords

enGene Holdings Inc., ENGN, Michael Thomas Heffernan, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule